Literature DB >> 2334211

High dose pancreatic enzymes in cystic fibrosis.

P J Robinson1, P D Sly.   

Abstract

Seven patients with cystic fibrosis taking high doses of pancreatin supplements were assessed to determine whether this dose was necessary to achieve adequate fat absorption. Patients reduced their intake from a group mean of 45 to 21 capsules a day. Five patients did not have any significant alteration in fat malabsorption while taking the reduced enzyme dose.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2334211      PMCID: PMC1792276          DOI: 10.1136/adc.65.3.311

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  2 in total

1.  Intestinal disease in cystic fibrosis.

Authors:  P S Baxter; J A Dickson; S Variend; C J Taylor
Journal:  Arch Dis Child       Date:  1988-12       Impact factor: 3.791

2.  Liver disease and common-bile-duct stenosis in cystic fibrosis.

Authors:  K J Gaskin; D L Waters; R Howman-Giles; M de Silva; J W Earl; H C Martin; A E Kan; J M Brown; S F Dorney
Journal:  N Engl J Med       Date:  1988-02-11       Impact factor: 91.245

  2 in total
  3 in total

Review 1.  Subclinical colonic thickening.

Authors:  P J Oades; M Rosenthal; E J Mac Sweeney; A Bush
Journal:  J R Soc Med       Date:  1996       Impact factor: 5.344

2.  Wechsler subscale IQ and subtest profile in early treated phenylketonuria.

Authors:  P V Griffiths; C Demellweek; N Fay; P H Robinson; D C Davidson
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

3.  A double blind lipase for lipase comparison of a high lipase and standard pancreatic enzyme preparation in cystic fibrosis.

Authors:  I M Bowler; S P Wolfe; H M Owens; T A Sheldon; J M Littlewood; M P Walters
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.